Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.

Swedish biotech startup AAX Biotech strengthens the management team with the appointment of Juan Astorga-Wells. He became new Senior Manager of Science & Development.

Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.

PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, focusing on the development of non-viral gene therapies coupled with minimally-invasive delivery technology.

Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.

German foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.

Organoid technology has emerged as one of the most groundbreaking and cutting-edge technologies in the biomedical field. It finds widespread applications in disease modeling, drug discovery and screening, companion diagnostics, cell therapy, regenerative medicine, and more.

MIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.

London-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.